Q fever
ORPHA:781DiseaseNot applicableAll ages
Фенотипы (HPO)62
Очень частый (80–99%)1
HP:0032252Granuloma
Частый (30–79%)12
HP:0000613Photophobia
HP:0000988Skin rash
HP:0001324Muscle weakness
HP:0001744Splenomegaly
HP:0001945Fever
HP:0002014Diarrhea
HP:0002017Nausea and vomiting
HP:0002315Headache
HP:0002910Elevated circulating hepatic transaminase concentration
HP:0003326Myalgia
HP:0003565Elevated erythrocyte sedimentation rate
HP:0012378Fatigue
Периодический (5–29%)34
HP:0000716Depression
HP:0000790Hematuria
HP:0000952Jaundice
HP:0000979Purpura
HP:0001392Abnormality of the liver
HP:0001433Hepatosplenomegaly
HP:0001511Intrauterine growth retardation
HP:0001518Small for gestational age
HP:0001562Oligohydramnios
HP:0001622Premature birth
HP:0001626Abnormality of the cardiovascular system
HP:0001824Weight loss
HP:0001873Thrombocytopenia
HP:0001878Hemolytic anemia
HP:0001903Anemia
HP:0002039Anorexia
HP:0002090Pneumonia
HP:0002240Hepatomegaly
HP:0002360Sleep abnormality
HP:0002633Vasculitis
HP:0002829Arthralgia
HP:0002922Increased CSF protein concentration
HP:0002923Rheumatoid factor positive
HP:0003262Smooth muscle antibody positivity
HP:0003613Antiphospholipid antibody positivity
HP:0010702Increased circulating antibody level
HP:0011227Elevated circulating C-reactive protein concentration
HP:0012115Hepatitis
HP:0012735Cough
HP:0020136Anticardiolipin IgG antibody positivity
HP:0030166Night sweats
HP:0033430Non-infectious meningitis
HP:0040186Maculopapular exanthema
HP:0100584Endocarditis
Очень редкий (1–4%)15
HP:0001082Cholecystitis
HP:0001287Meningitis
HP:0001698Pericardial effusion
HP:0001701Pericarditis
HP:0002098Respiratory distress
HP:0002202Pleural effusion
HP:0002383Infectious encephalitis
HP:0002716Lymphadenopathy
HP:0002754Osteomyelitis
HP:0005162Abnormal left ventricular function
HP:0006530Abnormal pulmonary interstitial morphology
HP:0011034Amyloidosis
HP:0012819Myocarditis
HP:0025343Lupus anticoagulant
HP:0100778Cryoglobulinemia
Эпидемиология24
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | <1 / 1 000 000 | 0.03 | United States | Value and class |
| Annual incidence | 1-9 / 100 000 | 3 | Australia | Value and class |
| Point prevalence | Unknown | — | Europe | Class only |
| Annual incidence | 1-9 / 1 000 000 | 0.16 | Europe | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.08 | Belgium | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.26 | Bulgaria | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.4 | Croatia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.32 | Cyprus | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.04 | Finland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.26 | France | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.26 | Germany | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.1 | Greece | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.64 | Hungary | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.06 | Ireland | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.07 | Latvia | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.04 | Luxembourg | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.1 | Malta | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.18 | Netherlands | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.2 | Portugal | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.1 | Romania | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.1 | Slovenia | Value and class |
| Annual incidence | <1 / 1 000 000 | — | Sweden | Class only |
| Annual incidence | 1-9 / 1 000 000 | 0.1 | United Kingdom | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.05 | Norway | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)